PRECIGEN, INC. Increase (Decrease) in Restricted Cash
PRECIGEN, INC. (PGEN) reported Increase (Decrease) in Restricted Cash of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCash · last filed 2018-03-01
- PRECIGEN, INC. increase (decrease) in restricted cash for the quarter ending 2017-12-31 was $0.00.
- PRECIGEN, INC. increase (decrease) in restricted cash for the quarter ending 2016-12-31 was $0.00.
- PRECIGEN, INC. increase (decrease) in restricted cash for the quarter ending 2015-12-31 was $0.00.
- PRECIGEN, INC. increase (decrease) in restricted cash for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- PRECIGEN, INC. increase (decrease) in restricted cash for fiscal 2016 was $6.99M.
- PRECIGEN, INC. increase (decrease) in restricted cash for fiscal 2015 was $0.00.
- PRECIGEN, INC. increase (decrease) in restricted cash for fiscal 2014 was $0.00.
| Period end | Increase (Decrease) in Restricted Cash 3 month | Increase (Decrease) in Restricted Cash 9 month | Increase (Decrease) in Restricted Cash 12 month |
|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 10-K · filed 2018-03-01 | |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-09 | ||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $6.99M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $6.99M 10-Q · filed 2017-11-09 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 10-K · filed 2018-03-01 | |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-09 | ||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |